BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 29427136)

  • 1. Molecular Alterations Associated with DNA Repair in Pancreatic Adenocarcinoma Are Associated with Sites of Recurrence.
    Ferguson MD; Dong L; Wan J; Deneve JL; Dickson PV; Behrman SW; Shibata D; Martin MG; Glazer ES
    J Gastrointest Cancer; 2019 Jun; 50(2):285-291. PubMed ID: 29427136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
    Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
    Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exome sequencing and digital PCR analyses reveal novel mutated genes related to the metastasis of pancreatic ductal adenocarcinoma.
    Zhou B; Irwanto A; Guo YM; Bei JX; Wu Q; Chen G; Zhang TP; Lei JJ; Feng QS; Chen LZ; Liu J; Zhao YP
    Cancer Biol Ther; 2012 Aug; 13(10):871-9. PubMed ID: 22797009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological impacts of DNA methylation alterations on pancreatic ductal adenocarcinoma: prediction of early recurrence based on genome-wide DNA methylation profiling.
    Endo Y; Fujimoto M; Ito N; Takahashi Y; Kitago M; Gotoh M; Hiraoka N; Yoshida T; Kitagawa Y; Kanai Y; Arai E
    J Cancer Res Clin Oncol; 2021 May; 147(5):1341-1354. PubMed ID: 33635431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Driver Mutations on the Evolution of Isolated Metachronous Lung Metastasis of Pancreatic Ductal adenocarcinoma.
    Vitellius C; Griveaux O; Morvant B; Pedrono E; Venara A; Ingster O; Baize N; Dincuff E; Rousselet MC; Guardiola P; Caroli-Bosc FX
    Mol Diagn Ther; 2020 Aug; 24(4):443-449. PubMed ID: 32524539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small Nucleolar Noncoding RNA SNORA23, Up-Regulated in Human Pancreatic Ductal Adenocarcinoma, Regulates Expression of Spectrin Repeat-Containing Nuclear Envelope 2 to Promote Growth and Metastasis of Xenograft Tumors in Mice.
    Cui L; Nakano K; Obchoei S; Setoguchi K; Matsumoto M; Yamamoto T; Obika S; Shimada K; Hiraoka N
    Gastroenterology; 2017 Jul; 153(1):292-306.e2. PubMed ID: 28390868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EP300--a miRNA-regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas.
    Mees ST; Mardin WA; Wendel C; Baeumer N; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
    Int J Cancer; 2010 Jan; 126(1):114-24. PubMed ID: 19569050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected pancreatic cancer: A correlation with clinical outcome.
    Dugnani E; Sordi V; Pellegrini S; Chimienti R; Marzinotto I; Pasquale V; Liberati D; Balzano G; Doglioni C; Reni M; Gandolfi A; Falconi M; Lampasona V; Piemonti L
    Pancreatology; 2018 Dec; 18(8):945-953. PubMed ID: 30293872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
    Zhao L; Zhao H; Yan H
    BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
    Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
    Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of B cell transposition gene 3 in pancreatic ductal adenocarcinoma and its prognostic value].
    Chen J; Zhou ZC; Liu WB; Wang J; Chen XJ; Shen YY; Zhong ZX
    Zhonghua Wai Ke Za Zhi; 2017 Nov; 55(11):863-867. PubMed ID: 29136736
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer.
    Umemoto K; Sunakawa Y; Ueno M; Furukawa M; Mizuno N; Sudo K; Kawamoto Y; Kajiwara T; Ohtsubo K; Okano N; Matsuhashi N; Itoh S; Matsumoto T; Shimizu S; Otsuru T; Hasegawa H; Okuyama H; Ohama H; Moriwaki T; Ohta T; Odegaard JI; Nakamura Y; Bando H; Yoshino T; Ikeda M; Morizane C
    Br J Cancer; 2023 Apr; 128(8):1603-1608. PubMed ID: 36782009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma.
    Chung C; Galvin R; Achenbach E; Dziadkowiec O; Sen S
    Oncology (Williston Park); 2021 Dec; 35(12):794-803. PubMed ID: 35089001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.
    Shin SH; Kim HJ; Hwang DW; Lee JH; Song KB; Jun E; Shim IK; Hong SM; Kim HJ; Park KM; Lee YJ; Kim SC
    Oncotarget; 2017 Mar; 8(11):17945-17959. PubMed ID: 28160547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
    Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
    Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.
    Baechmann S; Ormanns S; Haas M; Kruger S; Remold A; Modest DP; Kirchner T; Jung A; Werner J; Heinemann V; Boeck S
    BMC Cancer; 2017 May; 17(1):374. PubMed ID: 28549417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?
    Jordan EJ; Lowery MA; Basturk O; Allen PJ; Yu KH; Tabar V; Beal K; Reidy DL; Yamada Y; Janjigian Y; Abou-Alfa GK; O'Reilly EM
    Clin Colorectal Cancer; 2018 Jun; 17(2):e315-e321. PubMed ID: 29496399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.